Professor at Sun Yat-sen University Cancer Center, China
Liwu Fu, PhD, MD is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University, Guangzhou, China. 🎓 He earned his MD from Guangdong Medical and Pharmaceutical College, followed by an MS and PhD in Medicine from Sun Yat-sen University. 🏥 Dr. Fu completed a postdoctoral fellowship at the Medical University of South Carolina, USA. His research focuses on anticancer drug development and cancer pathophysiology. 🔬 With extensive experience in oncology and toxicology, he has held key academic and research positions since 1987.
Publication Profile
Scopus
🎓 Educational Background
📌 Liwu Fu has a strong academic foundation in medicine and cancer research. He earned his MD from Guangdong Medical and Pharmaceutical College (1987) 🏥. He then pursued an MS in Medicine (1993) and a PhD in Medicine (1996) at Sun Yat-sen University, specializing in toxicology and cancer research 🔬. Further advancing his expertise, he completed a postdoctoral fellowship (1999-2002) at the Medical University of South Carolina, USA, in pathology and laboratory medicine 🧬. His extensive education has shaped his contributions to oncology and anticancer drug development. 🎗️
💼 Professional Experience
🔬 Liwu Fu is a Professor and Director at the Cancer Institute, Cancer Center, Sun Yat-sen University (since 2002) 🏥. He previously served as an Associate Professor (1998-2002) and Lecturer, Deputy Head (1996-1998) in the Department of Anticancer Drug. His research was further enriched by a postdoctoral fellowship at the Medical University of South Carolina, USA (1999-2002) 🇺🇸. He has held key leadership roles, including Chairman of the Guangdong Cancer Pharmacological Society (since 2009) and Associate Director in multiple national cancer and pharmacology organizations 🎗️. He is also an AACR member and has contributed significantly to cancer pharmacology. 🚀
Research Focus
Dr. Liwu Fu’s research focuses on cancer biology 🔬, particularly in tumor immunology 🧬, drug resistance mechanisms 💊, and targeted therapies 🎯. His studies explore immune evasion through PD-L1 regulation, the role of extracellular vesicles in chemoresistance, and cancer stem cell-derived signals. He has contributed significantly to understanding lung cancer 🫁, colorectal cancer 🏥, and leukemia 🧑⚕️. His work also investigates innovative drug strategies like ERK and KRAS inhibitors, enhancing immune checkpoint therapies. His publications in high-impact journals demonstrate expertise in molecular oncology 🧫 and precision medicine 🏹, making key advancements in overcoming cancer treatment resistance.
Publication Top Notes
📌 Intra-tumoral Sphingobacterium multivorum Promotes Triple-Negative Breast Cancer Progression by Suppressing Tumor Immunosurveillance
🗓 Year: 2025 | Cited by: 2 | Molecular Cancer
📌 Effect of Extracellular Vesicles Derived From Tumor Cells on Immune Evasion
🗓 Year: 2025 | Advanced Science
📌 Resistance to Antibody–Drug Conjugates: A Review
🗓 Year: 2025 | Acta Pharmaceutica Sinica B
📌 PBA2, a Novel Inhibitor of the β-Catenin/CBP Pathway, Eradicates Chronic Myeloid Leukemia Including BCR-ABL T315I Mutation
🗓 Year: 2024 | Molecular Cancer
📌 BI-2865, a Pan-KRAS Inhibitor, Reverses the P-Glycoprotein Induced Multidrug Resistance In Vitro and In Vivo
🗓 Year: 2024 | Cited by: 2 | Cell Communication and Signaling
Conclusion
Professor Liwu Fu is a distinguished cancer researcher specializing in pharmacology, chemotherapy, multidrug resistance, and personalized cancer therapy. With over 200 publications in high-impact SCI journals and leadership in 40+ major research projects, his contributions to oncology are widely recognized. He has received prestigious honors, including the Chinese Anti-Cancer Association Science and Technology Award, and holds key roles in national and international cancer research organizations. Additionally, he serves on the editorial boards of top-tier cancer research journals and reviews for esteemed publications like Cancer Research and Journal of Pharmacology and Experimental Therapeutics. His groundbreaking work in overcoming multidrug resistance positions him as a strong candidate for the Best Researcher Award. 🚀🏆